Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial
Titel:
Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial
Auteur:
Goss, G.D. Felip, E. Cobo, M. Lu, S. Georgoulias, V. Ardizzoni, A. Gadgeel, S. Wang, B. Chand, V.K. Soria, J.-C.